3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Gastrointestinal Stromal Tumors
1
Interventions
Cyclophosphamide
13
fludarabine phosphate
10
Filgrastim
10
Imatinib Mesylate
9
Tacrolimus
8
Dasatinib
7
Peripheral Blood Stem Cell Transplantation
6
Mycophenolic Acid
6
Whole-Body Irradiation
5
Etoposide
5
Antilymphocyte Serum
5
sargramostim
4
Sirolimus
4
Radiotherapy
4
Cyclosporine
4
Cord Blood Stem Cell Transplantation
4
tanespimycin
3
Rituximab
3
Prednisone
3
Polymerase Chain Reaction
3
Methylprednisolone
3
Flow Cytometry
3
Doxorubicin
3
Carboplatin
3
Busulfan
3
tipifarnib
2
ruxolitinib
2
peginterferon alfa-2b
2
nilotinib
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid, Chronic-Phase
×
olverembatinib
×
Clear all
NCT03882281
2020-01-22
CML
Ascentage Pharma Group Inc.
Phase 1
Completed
12 enrolled